A large market built on pressure management.
Global glaucoma prevalence is projected to grow from approximately 76 million in 2020 to 112 million by 2040, yet no approved therapy restores the trabecular meshwork.
Pressure management, not disease modification.
The therapeutics market remains dominated by topical pressure-lowering drops, yet roughly half of patients are non-adherent, and no approved therapy restores the trabecular meshwork. OF-01 is designed to be used alongside existing therapy, intended to address the underlying tissue rather than the downstream pressure alone.
Market figures are approximate, drawn from published epidemiology and industry estimates for context only. Target launch window is early 2030s, contingent on clinical results, regulatory outcomes, and financing; this is a planning estimate, not a projection.
A fundamentally different target.
Once-daily drop
Conventional multi-dose bottle, no device or procedure.
Disease-modifying potential
Designed to restore TM function, not just lower pressure.
505(b)(2) pathway
Leverages prior findings for both components.
| Product | Class | Route | Mechanism focus | Status |
|---|---|---|---|---|
| Vyzulta (latanoprostene bunod) | PG analog + NO donor | Topical, once daily | Increases uveoscleral & trabecular outflow | FDA-approved |
| Rocklatan (netarsudil + latanoprost) | ROCK inhibitor + PG | Topical, once daily | Reduces episcleral venous pressure, increases outflow | FDA-approved |
| Durysta (bimatoprost implant) | Sustained-release prostaglandin | Intracameral, ~4-6 months | Sustained IOP lowering | FDA-approved |
| OF-01 (investigational) | 4-PBA + TUDCA chaperones | Topical, once daily (design) | Designed to restore TM function & conventional outflow | Investigational · IND-enabling |
OF-01 attributes are investigational design goals based on preclinical data only. Approved product attributes are summarized from public labeling for context and are not endorsed by their manufacturers.
We are not publishing a ten-year revenue forecast.
A single point estimate ten years before launch would be theater, not analysis. What we share here is the framing, the reference points, and the assumptions that govern a bottom-up model available to qualified investors under NDA.
The complete bottom-up model, including unit economics, adoption ramp, gross-to-net scenarios and sensitivities, is available to qualified investors under the data room.
What has to go right.
Generic PGA dominance.
Generic latanoprost is inexpensive, once daily, and entrenched as first line. Any branded entrant competes against a low-cost standard of care.
Step therapy and formulary access.
Payers typically require failure on generics first. Access, not efficacy alone, governs uptake and timing.
Adherence.
Glaucoma is chronic and asymptomatic early. Real-world persistence on topical therapy is poor, which is reflected in the 0.65 MPR assumption.
Clinical risk.
No human data exist for OF-01. The 505(b)(2) route reduces duplicative safety work; it does not reduce the requirement to demonstrate efficacy.